Healthcare / Medical Instruments & SuppliesNasdaqGS
$23.19
+0.31 (+1.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $12.4M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
21.1x
↑ROE
-3.2%
↓Gross Margin
45.5%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+6.4%
FCF CAGR
—
FCF margin
6.5%
FCF / Net income
-0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $593.8M · net income $-55.8M · FCF $38.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $593.8M | $593.8M | $573.4M | $551.5M | $555.5M | $513.7M | $388.5M | $334.2M | $631.6M | $527.5M | $434.0M | $552.7M | $482.8M | $422.4M | $489.0M | $688.1M | $593.0M | $218.7M |
| Net Income | $-55.8M | $-55.8M | $-164.9M | $-14.6M | $2.13B | $110.7M | $64.9M | $437.4M | $116.6M | $62.6M | $-69.5M | $14.2M | $31.4M | $-2.2M | $136.8M | $130.4M | $59.8M | $-227.9M |
| EBITDA | $39.5M | $39.5M | $50.9M | $28.9M | $30.3M | $34.2M | $28.9M | $7.0M | $68.8M | $42.5M | $11.0M | $42.0M | $20.8M | $7.4M | $23.3M | $96.8M | $65.4M | $-202.2M |
| EPS | -1.22 | -1.22 | -3.60 | -0.22 | 28.48 | 1.49 | 0.88 | 6.04 | 1.64 | 0.89 | -1.01 | 0.21 | 0.46 | -0.03 | 2.08 | 2.01 | 0.93 | -3.62 |
| Gross Margin | 45.5% | 45.5% | 44.4% | 43.4% | 46.0% | 47.5% | 44.3% | 40.3% | 39.0% | 37.7% | 36.1% | 34.2% | 34.7% | 31.3% | 32.6% | 32.4% | 28.0% | -2.7% |
| Operating Margin | -3.6% | -3.6% | -7.0% | -10.3% | -4.2% | -6.1% | -9.4% | -14.2% | 5.0% | 2.7% | -3.9% | 3.1% | -0.6% | -4.0% | 0.3% | 11.6% | 7.9% | -104.3% |
| Net Margin | -9.4% | -9.4% | -28.8% | -2.7% | 384.0% | 21.6% | 16.7% | 130.9% | 18.5% | 11.9% | -16.0% | 2.6% | 6.5% | -0.5% | 28.0% | 18.9% | 10.1% | -104.2% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.04 | 0.04 | 0.04 | 0.27 | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.83 | 2.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $38.3M | $38.3M | $12.4M | $-33.6M | $-543.5M | $97.1M | $-2.1M | $67.0M | $61.2M | $83.5M | $26.7M | $27.6M | $48.3M | $50.8M | $27.4M | $81.2M | $24.4M | $-67.8M |
| Returns | ||||||||||||||||||
| ROE | -3.2% | -3.2% | -9.3% | -0.6% | 63.4% | 8.4% | 5.3% | 38.4% | 16.2% | 10.3% | -12.5% | 2.2% | 4.9% | -0.4% | 21.1% | 25.2% | 15.4% | — |
| Valuation | ||||||||||||||||||
| P/E | — | — | — | — | 1.47 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 21.14 | 21.14 | 38.84 | 92.26 | 83.55 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.62 | 0.62 | 1.24 | 1.30 | 0.93 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 3.6% | 3.6% | 4.0% | -0.7% | — | 32.2% | 16.3% | -47.1% | 19.7% | 21.5% | -21.5% | 14.5% | 14.3% | -13.6% | -28.9% | 16.0% | 171.1% | — |
| EPS Growth | 66.1% | 66.1% | -1537.5% | -100.8% | — | 69.3% | -85.4% | 268.3% | 84.3% | 188.1% | -581.0% | -54.3% | 1633.3% | -101.4% | 3.5% | 116.1% | 125.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.60 → -1.22
Residual
-13.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.